Parkinson's Disease
Conditions
Brief summary
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, but still experience periods of time when their medication does not adequately control their motor symptoms. Some may also experience dyskinesia (other type of involuntary movements) as a side effect of their PD medications. The main goal of the trial is to learn whether adding Lu AF28996 to participants' optimized PD medications will help extending the time they spend with their movement symptoms being well-controlled and without bothersome dyskinesia.
Interventions
DRUGLu AF28996
Lu AF28996 will be administered orally per schedule specified in the arm description.
DRUGPlacebo
Placebo matching to Lu AF28996 will be administered orally per schedule specified in the arm description.
Sponsors
H. Lundbeck A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * The participant was diagnosed with PD ≥3 years ago, with the diagnosis being established after the age of 30 years and consistent with the Movement Disorders Society (MDS) Clinical Diagnostic Criteria for "clinically established" or "clinically probable" PD. * The participant has a modified Hoehn and Yahr scale (mH\&Y) stage ≤3 in the ON state and ≥2 and ≤4 in the OFF state. * The participant reports well recognizable, consistent motor fluctuations causing significant disability per investigator's judgement over a period of ≥3 months prior to screening. * The participants report motor fluctuations each day as measured by OFF-time during awake hours. Key
Exclusion criteria
* The participant has previously been dosed with Lu AF28996. * The participant has participated in a clinical trial \<30 days prior to screening. * The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods. * The participant has taken any investigational medicinal product (IMP) \<3 months or \<5 half-lives, whichever is longer, prior to screening. * The participant has a Montréal Cognitive Assessment (MoCA) score ≤24 (adjusted for education). * The participant has an atypical, secondary, or drug-induced Parkinsonism (for example, metoclopramide, flunarizine), metabolic identified neurogenetic disorders (for example, Wilson's disease), encephalitis, or Parkinson Plus syndromes or other forms of atypical Parkinsonian syndromes (for example, progressive supranuclear palsy and multiple system atrophy). * The participant has severe, pervasive, disabling dyskinesia which, in the setting of the present trial, may interfere with his/her safe participation in the trial (for example, threat to falling, aspiration, etc.) as judged by the investigator. * The participant has unpredictable motor fluctuations as evidenced by an MDS-UPDRS Part IV Item 4.5 score ≥3 at screening and/or experiences wide, unpredictable fluctuations of PD symptoms per investigator's clinical judgement. Note: Other protocol defined inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline to Week 19 in Daily Good ON Time Based on the Participant's Hauser Diary Entries | Baseline, Week 19 |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline to Week 19 in Daily OFF Time Based on Participant's Hauser Diary Entries | Baseline, Week 19 |
| Change From Baseline to Week 19 in Daily ON Time With Troublesome Dyskinesia Based on Participant's Hauser Diary Entries in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's Unified Dyskinesia Rating Scale (UDysRS) Total Score in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline | Baseline, Week 19 |
| Participant's Achievement at Week 19 of a Reduction in Daily OFF Time, Defined as >1.5 Hour/Day Reduction | Week 19 |
| Participant's Achievement at Week 19 of an Increase in Daily Good ON Time >1.5 Hour/Day | Week 19 |
| Participant's Achievement at Week 19 of a Reduction in Both Daily ON Time With Troublesome Dyskinesia AND in OFF time in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline | Week 19 |
| Change From Baseline to Week 19 in Clinical Global Impression - Severity of Illness (CGI-S) Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's Movement Disorder Society-Unified Parkinson's Disease-Rating Scale (MDS-UPDRS) Part III Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's Movement Disorders Society Non-Motor Rating Scale (MDS-NMS) Domain Scores and Total Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's Parkinson's Disease Sleep Scale Version 2 (PDSS-2) Total Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's MDS-UPDRS Part IV (B) (Questions 4.1, 4.2, 4.3, 4.4 Item Scores), and Part IV Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's MDS-UPDRS Total Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's MDS-UPDRS Part I Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's MDS-UPDRS Part II Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's Parkinson's Disease Questionnaire-39 (PDQ-39) Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale Score | Baseline, Week 19 |
| Change From Baseline to Week 19 in Daily Oral Levodopa (mg) | Baseline, Week 19 |
| Change From Baseline to Week 19 in Levodopa-equivalent Dose (LED) | Baseline, Week 19 |
| Change From Baseline to Week 19 in Total Levodopa-equivalent Daily Dose (LEDD) | Baseline, Week 19 |
| Patient Global Impression of Change (PGI-C) Score at Week 19 | Week 19 |
| Plasma Concentrations of Lu AF28996 and Metabolites | Weeks 7 and 15 |
| Change From Baseline to Week 19 in Daily ON Time With Troublesome Dyskinesia Based on Participant's Hauser Daily Entries | Baseline, Week 19 |
| Change From Baseline to Week 19 in Daily ON Time Without Troublesome Dyskinesia Based on Participant's Hauser Daily Entries | Baseline, Week 19 |
| Change From Baseline to Week 19 in Daily ON Time With Non-troublesome Dyskinesia Based on Participant's Hauser Daily Entries | Baseline, Week 19 |
| Change From Baseline to Week 19 in Participant's UDysRS Total Score and Combined Partial Scores of Part 1 + Part 2, Part 3 + Part 4, and Part 1 + Part 3 + Part 4, in Participants With UDysRS Total Score ≥20 at Baseline | Baseline, Week 19 |
| Number of Participants With Achievement of a Reduction in Daily ON Time With Troublesome Dyskinesia at Week 19 | Week 19 |
| Number of Participants With Achievement of No Worsening in Daily ON Time With Troublesome Dyskinesia at Week 19 | Week 19 |
Contacts
CONTACTEmail contact via H. Lundbeck A/S
STUDY_DIRECTOREmail contact via H. Lundbeck A/S
H. Lundbeck A/S
Outcome results
None listed